[go: up one dir, main page]

IN2012DN04944A - - Google Patents

Download PDF

Info

Publication number
IN2012DN04944A
IN2012DN04944A IN4944DEN2012A IN2012DN04944A IN 2012DN04944 A IN2012DN04944 A IN 2012DN04944A IN 4944DEN2012 A IN4944DEN2012 A IN 4944DEN2012A IN 2012DN04944 A IN2012DN04944 A IN 2012DN04944A
Authority
IN
India
Prior art keywords
expression level
polq
breast cancer
patient
gene
Prior art date
Application number
Inventor
Christophe Cazaux
Jean-Sebastien Hoffmann
Jean-Christophe Bourdon
Da Silva Alice Machado
Henri Roche
Original Assignee
Centre Nat Rech Scient
Univ Toulouse 3 Paul Sabatier
Inst Claudius
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Toulouse 3 Paul Sabatier, Inst Claudius filed Critical Centre Nat Rech Scient
Publication of IN2012DN04944A publication Critical patent/IN2012DN04944A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

The present invention relates to a method for diagnosing aggressiveness and/or genetic instability of a breast cancer in a patient from a breast cancer sample of said patient, comprising: a) measuring in vitro the expression level of the POLQ gene and the expression level of a control gene in said patient breast cancer sample; b) calculating for said POLQ gene an expression level ratio of the expression level of POLQ to the expression of the said control gene in said patient breast cancer sample; c) comparing the said POLQ expression level ratio to a corresponding threshold value, and d) diagnosing breast cancer aggressiveness and genetic instability if the said POLQ expression level ratio is superior to a corresponding threshold values. Dedicated microarrays and kits are also described, as well as a method of selecting a suitable treatment.
IN4944DEN2012 2009-11-13 2010-11-12 IN2012DN04944A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09306096A EP2322658A1 (en) 2009-11-13 2009-11-13 Signature for the diagnosis of breast cancer aggressiveness and genetic instability
PCT/EP2010/067401 WO2011058143A1 (en) 2009-11-13 2010-11-12 Signature for the diagnosis of breast cancer aggressiveness and genetic instability

Publications (1)

Publication Number Publication Date
IN2012DN04944A true IN2012DN04944A (en) 2015-09-25

Family

ID=41647234

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4944DEN2012 IN2012DN04944A (en) 2009-11-13 2010-11-12

Country Status (11)

Country Link
US (1) US8865408B2 (en)
EP (2) EP2322658A1 (en)
CN (1) CN102791879A (en)
AU (1) AU2010317877A1 (en)
BR (1) BR112012011247A2 (en)
CA (1) CA2780479A1 (en)
ES (1) ES2522992T3 (en)
IL (1) IL219697A0 (en)
IN (1) IN2012DN04944A (en)
PT (1) PT2499258E (en)
WO (1) WO2011058143A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103827314A (en) * 2011-05-18 2014-05-28 国家科学研究中心 Signature for the diagnosis of cancer aggressiveness and genetic instability
CA2860549A1 (en) 2012-01-05 2013-07-11 Christophe Cazaux Signature for the diagnosis of lung cancer aggressiveness and genetic instability
CN102994627B (en) * 2012-06-21 2015-04-15 宁波海尔施基因科技有限公司 Detection method of individual guidance of drug for tumor
US9157124B2 (en) 2012-09-18 2015-10-13 Institute For Cancer Research Systems and methods for diagnosing a predisposition to develop colon cancer
FR3019821A1 (en) * 2014-04-14 2015-10-16 Centre Nat Rech Scient NEW ANTIBODIES USEFUL FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER
US10724100B2 (en) 2015-09-16 2020-07-28 Institute For Cancer Research Systems and methods for treating patients having a genetic predisposition to develop prostate cancer
US10760081B2 (en) 2015-10-07 2020-09-01 New York University Compositions and methods for enhancing CRISPR activity by POLQ inhibition
AU2016340878A1 (en) * 2015-10-19 2018-05-10 Dana-Farber Cancer Institute, Inc. Polymerase Q as a target in HR-deficient cancers
CN106011262A (en) * 2016-06-29 2016-10-12 北京泱深生物信息技术有限公司 Endometrial cancer diagnosis and treatment marker and application thereof
WO2020014297A1 (en) * 2018-07-11 2020-01-16 The Johns Hopkins University Identification of dna polymerase theta inactivation mechanism
EP3906564A4 (en) 2018-12-31 2022-09-07 Tempus Labs, Inc. METHOD AND APPARATUS FOR PREDICTION AND ANALYSIS OF PATIENT COHORT RESPONSE, PROGRESSION AND SURVIVAL
US11875903B2 (en) 2018-12-31 2024-01-16 Tempus Labs, Inc. Method and process for predicting and analyzing patient cohort response, progression, and survival
CN112725444A (en) * 2020-12-30 2021-04-30 杭州联川基因诊断技术有限公司 Primer, probe, kit and detection method for detecting PGR gene expression
CN112646864A (en) * 2020-12-30 2021-04-13 杭州联川基因诊断技术有限公司 Primer, probe, kit and detection method for detecting ESR1 gene expression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101146806B1 (en) 2003-03-12 2012-05-22 메이브릿지 리미티드 Phthalazinone derivatives
BRPI0417056A (en) 2003-12-01 2007-02-06 Kudos Pharm Ltd DNA Damage Repair Inhibitors for Cancer Treatment
US20090081119A1 (en) 2005-05-19 2009-03-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Inhibiting dna polymerase beta to enhance efficacy of anticancer agents
AT504702A1 (en) * 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh SET OF TUMOR MARKERS
KR20120090100A (en) 2006-12-26 2012-08-16 파마시클릭스, 인코포레이티드 Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
JP5439380B2 (en) 2007-10-03 2014-03-12 エーザイ インク． PARP inhibiting compounds, compositions and methods of use

Also Published As

Publication number Publication date
BR112012011247A2 (en) 2016-11-22
EP2499258B1 (en) 2014-08-06
ES2522992T3 (en) 2014-11-20
US8865408B2 (en) 2014-10-21
EP2322658A1 (en) 2011-05-18
WO2011058143A1 (en) 2011-05-19
EP2499258A1 (en) 2012-09-19
US20120021935A1 (en) 2012-01-26
CN102791879A (en) 2012-11-21
IL219697A0 (en) 2012-07-31
AU2010317877A1 (en) 2012-06-07
CA2780479A1 (en) 2011-05-19
PT2499258E (en) 2014-11-04

Similar Documents

Publication Publication Date Title
IN2012DN04944A (en)
Chi et al. Downregulation of hsa_circ_0000285 serves as a prognostic biomarker for bladder cancer and is involved in cisplatin resistance.
UA110790C2 (en) METHOD FOR PREVENTING BREAST CANCER RECURRENCE IN ENDOCRINARY TREATMENT
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
WO2013182912A3 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
AR061136A1 (en) PROCESS
HK1213946A1 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
WO2014140933A8 (en) Method for the prognosis and treatment of cancer metastasis
WO2012045905A3 (en) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
WO2011122857A3 (en) Composition for predicting prognosis of breast cancer, and kit containing same
NZ705645A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
MX366164B (en) Gene expression profile algorithm and test for determining prognosis of prostate cancer.
WO2011153545A3 (en) Gene expression signature as a predictor of chemotherapeutic response in breast cancer
MX391499B (en) METHODS FOR PREDICTING THE CLINICAL OUTCOME OF CANCER.
MX2009010439A (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment.
EP4083233A3 (en) Method for using gene expression to determine prognosis of prostate cancer
WO2015052583A3 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
WO2012174256A3 (en) Dna methylation profiles in cancer
WO2008037700A3 (en) Methods for breast cancer prognosis
ATE481504T1 (en) GENETIC MODIFICATION SUITABLE FOR PREDICTING THE RESPONSE OF MALIGNANT NEOPLASIA TO TAXAN-BASED MEDICAL TREATMENT
IN2012DN01979A (en)
MX2011007795A (en) Polynucleotide comprising sequences of wheat gliadins and use thereof for silencing by rnai.
EA201290107A1 (en) METHOD FOR DETERMINING A PATIENT AS A SUSTAINABLE OR NOT SUSTAINABLE FOR IMMUNOTHERAPY
MX2013004747A (en) Peripheral blood gene markers for early diagnosis of parkinson's disease.
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer